March 10, 2025· 43 min

Here Comes the Booming Chinese Biotech Sector

Tim Opler

Orality

Model

86%

Highly oral (epic poetry, sermons, hip-hop)

Speaker Breakdown

HostTracy Alloway(1,955 words)

M:94%

HostJoe Weisenthal(1,110 words)

M:94%

GuestTim Opler(4,534 words)

M:94%

Oral Indicators

Agonistic27%

very, certainly, basically

Engagement69%

you, our, your

Memory Aids100%

listen, so, see

Repetition100%

like (111x), know (75x), they (74x)

Parallelism68%

So we have Sarah Fuentes from ..., And I'm Tracy Alloway...., And then more generally, it so...

Sound Patterns88%

74 question(s), alliteration: "markets move", alliteration: "barclays brief"

Formulaic Phrases5%

you know what, i mean

Literate Indicators

Hedging8%

may, quite, could

Passive Voice6%

been approved, were focused, been developed

Abstract Nouns17%

investment, business, chase.com/business

Subordination6%

because, though, until

Sentence Length31%

Avg: 12.8 words/sentence

Word Complexity47%

investment, analyze, anticipate

Academic Markers0%

Impersonal Style31%

575 personal pronouns found

Descriptive Style87%

apply, finally, actually

Description

You’ve heard about Chinese EVs. You’ve heard about Chinese batteries and solar panels. And recently you learned that China is near the cutting edge of AI research. Here’s another category: biotech. In 2019, the Chinese share of molecules licensed to Big Pharma companies was 0%. In 2024, it’s now 31%. On this episode we speak with Tim Opler, a biotech industry investment banker at Stifel. He explains how this industry has taken off in such a short period of time. Among the factors he cites: a generation of Chinese research scientists working in the US who hit a ceiling in terms of promotion and thus went back home to start companies. It’s also far cheaper to run clinical trials in China, due to the structure of the healthcare system. We also talk about the broad history of the pharmaceutical industry, how it’s evolved, and what impact, if any, AI will have on drug discovery. Read More: Former J&J Scientist Bets on China Biotech Chinese Health Stocks Surge on DeepSeek Integration Potential Odd Lots is coming to Washington, DC! Get your tickets for our Jones Act debate here. See omnystudio.com/listener for privacy information.

← Trump's NIH Cuts Send Shockwaves Through...Cathie Wood on What Comes Next in AI and... →